Analgesics and anesthetics during peripartum period


Our focus in KuBiCo–project is to evaluate the fetal and newborn effects of analgesics and anesthetics given for parturient during peripartum period. Maternal pharmacokinetics and –dynamics of different compounds used for pain relief and anesthesia will be measured. Fetal and newborn exposure will be estimated based on the drug concentrations in the placental venous and arterial blood. Pharmodynamic effects of these compounds on newborns will be tested with a comprehensive neurological and adaptive capacity evaluation, and by recording amplitude integrated EEG. All these measures are painless for newborn.

Group leader, Hannu Kokki, Prof.
University of Eastern Finland,
School of Medicine
Department of Anesthesia and Operative Services
Kuopio University Hospital PO Box 1627,
70211 Kuopio, Finland
email: hannu.kokki (at)
tel: +3587174654


  • Kokki M, Franco MG, Raatikainen K, Välitalo P, Sankilampi U, Heinonen S, Neuvonen PJ, Kokki H. Intravenous oxycodone for pain relief in the first stage of labour--maternal pharmacokinetics and neonatal exposure. Basic Clin Pharmacol Toxicol. 2012 Sep;111(3):182-8.
  • Kokki M, Sjövall S, Keinänen M, Kokki H. The influence of timing on the effectiveness of epidural blood patches in parturients. Int J Obstet Anesth. 2013 Nov;22(4):303-9.
  • Kokki M, Välitalo P, Kuusisto M, Ranta VP, Raatikainen K, Hautajärvi H, Kokki H. Central nervous system penetration of oxycodone after intravenous and epidural administration. Br J Anaesth. 2014 Jan;112(1):133-40.
  • Räisänen S, Kokki M, Kokki H, Gissler M, Kramer MR, Heinonen S. The use of epidural analgesia for intrapartum pain relief in publicly funded healthcare. Acta Anaesthesiol Scand. 2014 Jan 17. doi: 10.1111/aas.12268. [Epub ahead of print]